XRTX Key Statistics, Chart & Performance
The current stock price of XRTX is 0.49 USD. In the past month the price decreased by -18.33%. In the past year, price decreased by -44.87%.
XRTX Technical Analysis
XRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XRTX. XRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XRTX Financial Highlights
Over the last trailing twelve months XRTX reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -1213.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.13% | ||
| ROE | -98.46% | ||
| Debt/Equity | 0 |
XRTX Forecast & Estimates
XRTX Ownership
XRTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 33.42 | 948.651B | ||
| JNJ | JOHNSON & JOHNSON | 20.28 | 561.608B | ||
| MRK | MERCK & CO. INC. | 21.87 | 287.517B | ||
| PFE | PFIZER INC | 8.92 | 146.521B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 113.982B | ||
| ZTS | ZOETIS INC | 18.49 | 53.945B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.42 | 24.804B | ||
| VTRS | VIATRIS INC | 5.69 | 15.756B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.14 | 12.098B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.14 | 9.444B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XRTX
Company Profile
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Company Info
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
XORTX THERAPEUTICS INC / XRTX FAQ
What does XORTX THERAPEUTICS INC do?
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
What is the stock price of XORTX THERAPEUTICS INC today?
The current stock price of XRTX is 0.49 USD. The price decreased by -2.47% in the last trading session.
What is the dividend status of XORTX THERAPEUTICS INC?
XRTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of XRTX stock?
XRTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the next earnings date for XRTX stock?
XORTX THERAPEUTICS INC (XRTX) will report earnings on 2026-03-30, after the market close.